臨床外科79巻9号

2024年09月発行

特集 徹底解説　大腸癌治療ガイドライン2024

詳説

周術期薬物療法の前にバイオマーカー検査は推奨されるか？

著者： 川上尚人¹

所属機関： ¹近畿大学医学部内科学腫瘍内科部門

ページ範囲：P.1004 - P.1011

文献概要

【ポイント】
◆大腸癌周術期において，現在，実臨床で使用可能なバイオマーカーに基づく前向きランダム化比較試験は行われていない．
◆RASおよびBRAF遺伝子変異の情報は予後予測に役立つ可能性があり，これらに対する検査を行うことが弱く推奨される．
◆高頻度マイクロサテライト不安定性/ミスマッチ修復機能欠損（MSI-H/dMMR）についてはStage Ⅱ/Ⅲの術後補助化学療法の治療方針に影響するため，検査実施が強く推奨される．

参考文献

1）Rui YY, Zhang D, Zhou ZG, et al：Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review. PLoS One 8：e77901, 2013

Mutations in Stage Ⅱ and Ⅲ Colon Cancer：A Systematic Review and Meta-Analysis. J Natl Cancer Inst 114：517-527, 2022

3）Zhu L, Dong C, Cao Y, et al：Prognostic Role of BRAF Mutation in Stage Ⅱ/Ⅲ Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy：A Meta-Analysis Based on Randomized Clinical Trials. PLoS One 11：e0154795, 2016

Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol 33：4176-4187, 2015

5）Des Guetz G, Schischmanoff O, Nicolas P, et al：Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer 45：1890-1896, 2009

6）Guastadisegni C, Colafranceschi M, Ottini L, et al：Microsatellite instability as a marker of prognosis and response to therapy：a meta-analysis of colorectal cancer survival data. Eur J Cancer 46：2788-2798, 2010

7）Ribic CM, Sargent DJ, Moore MJ, et al：Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349：247-257, 2003

mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29：1261-1270, 2011

9）Sargent DJ, Marsoni S, Monges G, et al：Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28：3219-3226, 2010

10）Cohen R, Taieb J, Fiskum J, et al：Microsatellite Instability in Patients With Stage Ⅲ Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin：An ACCENT Pooled Analysis of 12 Adjuvant Trials. J Clin Oncol 39：642-651, 2021

mutation is associated with distinct clinicopathological characteristics in colorectal cancer：a systematic review and meta-analysis. Colorectal Dis 15：e711-e718, 2013

mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy：a systemic review and meta-analysis. Int J Colorectal Dis 36：1781-1790, 2021

13）O'Connell E, Reynolds IS, McNamara DA, et al：Microsatellite instability and response to neoadjuvant chemoradiotherapy in rectal cancer：A systematic review and meta-analysis. Surg Oncol 34：57-62, 2020

14）Swets M, Graham Martinez C, van Vliet S, et al：Microsatellite instability in rectal cancer：what does it mean? A study of two randomized trials and a systematic review of the literature. Histopathology 81：352-362, 2022

15）Cercek A, Lumish M, Sinopoli J, et al：PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med 386：2363-2376, 2022

mutations and survival after resection of colorectal liver metastases. Br J Surg 102：1175-1183, 2015

mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. Crit Rev Oncol Hematol 99：150-157, 2016

Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection：A Systematic Review and Meta-Analysis. Clin Colorectal Cancer 16：e153-e163, 2017

mutations on clinical outcomes following liver surgery for colorectal liver metastases：An updated meta-analysis. Eur J Surg Oncol 47：2722-2733, 2021

mutation in patients undergoing pulmonary metastasectomy for colorectal cancer：A systematic review and meta-analysis. Crit Rev Oncol Hematol 160：103308, 2021